{
  "profile_url": "https://www.moffitt.org/research-science/researchers/jhanelle-gray/",
  "last_updated": "2025-11-21T22:50:24.432302",
  "researcher_id": "3726",
  "degrees": [
    "MD"
  ],
  "title": "",
  "primary_program": "thoracic oncology",
  "research_program": "molecular medicine",
  "overview": "My research focus is to evaluate new molecular targets and biomarkers in lung cancer to reduce chemotherapy resistance and advance patient-specific therapy.",
  "research_interests": [
    "Dr. Gray\u2019s research focuses on the analysis of targeted therapies in patients with non-small cell lung cancer (NSCLC) and those at risk for lung cancer with hopes of optimizing the therapeutic benefit while minimizing the toxicity with the use of biomarker analysis to enhance the understanding of cancer biology and treatment.She was the principal investigator of a phase IIB randomized, placebo-controlled, double-blind study of enzastaurin (a protein kinase C inhibitor), investigating its efficacy in lung cancer prevention in former smokers. Through her continued work on this project, she was awarded an NIH Specialized Program of Research Excellence (SPORE) supplement grant (Research Supplements to Promote Diversity in Health-Related Research). Additionally Dr. Gray is involved in analyzing histone deacetylase (HDAC) inhibitors as a novel treatment approach in patients with lung cancer. One strategy to enhance the efficacy of the EGFR tyrosine kinase inhibitor, already demonstrated in vitro, is to combine erlotinib with inhibitors of other key oncogenic pathways such as HDAC inhibitors. Dr. Gray and colleagues also are exploring additional HDAC inhibitor combination strategies for clinical application.\n  *"
  ],
  "associations": [
    "Thoracic Oncology",
    "Tumor Microenvironment and Metastasis",
    "Lung Cancer Center of Excellence",
    "Molecular Medicine Program",
    "Experimental Therapeutics Program",
    "Cancer Chemoprevention Research Interest Group",
    "Melanoma & Skin Cancer Center of Excellence"
  ],
  "education": [
    {
      "type": "Medical School",
      "institution": "Weill Medical College of Cornell University, New York, NY",
      "degree": "MD"
    },
    {
      "type": "Residency",
      "institution": "The New York Presbyterian Hospital, New York, NY",
      "specialty": ""
    },
    {
      "type": "Fellowship",
      "institution": "H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL",
      "specialty": "Hematology/Oncology"
    },
    {
      "type": "Board Certification",
      "institution": "Internal Medicine",
      "certification": "Medical Oncology"
    },
    {
      "type": "Board Certification",
      "institution": "Internal Medicine",
      "certification": "Hematology"
    }
  ],
  "publications": [
    {
      "title": "Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung Cancer",
      "pubmed_id": "40498298",
      "pmc_id": "PMC12378254",
      "year": "2025",
      "publication_date": "2025 Sep",
      "authors": "Garassino MC, Cheng Y, Rodriguez-Abreu D, Novello S, Mazieres J, Robinson AG, Powell SF, Halmos B, Gray JE, Wang M, Chen C, Yang J, Souza F, Schwarzenberger P, Paz-Ares L",
      "journal": "Oncol Ther"
    },
    {
      "title": "Validation of the Functional Assessment of Cancer Therapy - Immune Checkpoint Modulator 17-Item Symptom Index (FACT-ICM-17) to facilitate implementation in research and clinical care",
      "pubmed_id": "41045471",
      "year": "2025",
      "publication_date": "2025 Oct",
      "authors": "Gudenkauf LM, Tometich DB, Hoogland AI, Li X, Kirtane K, Small BJ, Barata A, Gonzalez BD, Jacobs KD, Chung CH, Shafique MR, Gray J, Khushalani NI, Postow MA, Cella D, Webster KA, Dicker AP, Jim HSL",
      "journal": "Cancer"
    },
    {
      "title": "Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabb\u00f3 F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Leighl NB, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, J\u00e4nne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. N ...",
      "authors": ""
    },
    {
      "title": "Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929",
      "pubmed_id": "39505259",
      "year": "2025",
      "publication_date": "2025 Mar",
      "authors": "Karim NA, Miao J, Reckamp KL, Gay CM, Byers LA, Zhao YQ, Redman MW, Carrizosa DR, Wang WL, Petty WJ, Mehta K, Faller BA, Agamah ES, Kasbari SS, Malisetti RK, Kumar A, Schallenkamp J, Alluri KC, Gray JE, Kelly K",
      "journal": "J Thorac Oncol"
    },
    {
      "title": "EGFR mutation testing across the osimertinib clinical program",
      "pubmed_id": "40311309",
      "year": "2025",
      "publication_date": "2025 Jun",
      "authors": "Murat-Onana ML, Ramalingam SS, J\u00e4nne PA, Gray JE, Ahn MJ, John T, Yatabe Y, Huang X, Rukazenkov Y, Javey M, Brown H, Li-Sucholeiki X",
      "journal": "Lung Cancer"
    },
    {
      "title": "Timeliness of Newer Targeted Therapy and Survival in Lung Cancer: A Population-Based Analysis",
      "pubmed_id": "40472300",
      "year": "2025",
      "publication_date": "2025 Jun",
      "authors": "Tanvetyanon T, Joshi U, Chen DT, Gray JE",
      "journal": "JCO Oncol Pract"
    },
    {
      "title": "Real-World Clinical Characteristics, Treatment Patterns, and Clinical Outcomes in US Patients with Stage I-III Resected NSCLC Without Known EGFR Mutations: The RESECT Study",
      "pubmed_id": "40329045",
      "pmc_id": "PMC12174031",
      "year": "2025",
      "publication_date": "2025 Jun",
      "authors": "Gray JE, Salomonsen RJ, Diaz Perez I, Wang A, Cai L, Wetherill G, Xiao Y, Fielden C, Georgoulia N",
      "journal": "Drugs Real World Outcomes"
    },
    {
      "title": "Patient, care partner, and provider voice in treatment decision-making for non-small cell lung cancer",
      "pubmed_id": "40215576",
      "year": "2025",
      "publication_date": "2025 Jul",
      "authors": "Orr LD, Vanderpoel J, Vadagam P, Patel MI, Roy UB, Ledezma B, Yung M, Deering KL, Kulbokas V, Feldman J, Gray JE",
      "journal": "Patient Educ Couns"
    },
    {
      "title": "Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC",
      "pubmed_id": "39260522",
      "year": "2025",
      "publication_date": "2025 Jan",
      "authors": "Nassar AH, Jayakrishnan R, Feng J, Shepherd F, Adib E, Cheung JM, Lin JJ, Liu Y, Lin SH, Parikh K, Sridhar A, Shakya P, Dilling TJ, Kaldas D, Gray JE, Lobachov A, Bar J, Luders H, Grohe C, Gupta S, Leal T, Fitzgerald B, Crowley F, Fujiwara Y, Marron TU, Wilgucki M, Reuss J, Chen L, Sankar K, Aredo JV, Neal JW, Wakelee HA, Thummalapalli R, Yu H, Whitaker R, Velazquez A, Ragavan M, Cortellini A, Kwiatkowski DJ, Naqash AR, Goldberg SB, Kim SY",
      "journal": "J Thorac Oncol"
    },
    {
      "title": "A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Na\u00efve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial)",
      "pubmed_id": "39378386",
      "pmc_id": "PMC11776886",
      "year": "2025",
      "publication_date": "2025 Feb",
      "authors": "Le X, Patel JD, Shum E, Baik C, Sanborn RE, Shu CA, Kim C, Fidler MJ, Hall R, Elamin YY, Tu J, Blumenschein G, Zhang J, Gibbons D, Gay C, Mohindra NA, Chae Y, Boumber Y, Sabari J, Santana-Davila R, Rogosin S, Herzberg B, Creelan B, Pellini B, Tanvetyanon T, Heeke S, Hernandez M, Gray JE, Saltos A, Heymach JV",
      "journal": "J Clin Oncol"
    }
  ],
  "grants": [
    {
      "description": "Title: Modernize Adverse Event (AE) Data to Develop Predictive AE Biomarkers for Fulfilling Oncological Precision Medicine  \nAward Number: MOAAX  \nSponsor: Florida Department of Health  \nChen, D. (PD/PI), Gray, J. (Co-PD/PI)",
      "title": "Modernize Adverse Event (AE) Data to Develop Predictive AE Biomarkers for Fulfilling Oncological Precision Medicine",
      "award_number": "MOAAX",
      "sponsor": "Florida Department of Health",
      "investigators": [
        {
          "name": "Chen, D.",
          "role": "PD/PI"
        },
        {
          "name": "Gray, J.",
          "role": "Co-PD/PI"
        }
      ]
    },
    {
      "description": "Title: Community Outreach to Empower Black Patients with NSCLC to Improve Engagement and Awareness (COMPASS)  \nAward Number:   \nSponsor: FOUNDATION MEDICINE INC.  \nGray, J. (PD/PI)",
      "title": "Community Outreach to Empower Black Patients with NSCLC to Improve Engagement and Awareness (COMPASS)",
      "award_number": "",
      "sponsor": "FOUNDATION MEDICINE INC.",
      "investigators": [
        {
          "name": "Gray, J.",
          "role": "PD/PI"
        }
      ]
    },
    {
      "description": "Title: Community Project Funding/Congressionally Directed Spending Construction - Mobile Lung Screening Program  \nAward Number: 1CE1HS52205?01?00  \nSponsor: Health Resources and Services Administration (HRSA)  \nGray, J. (PD/PI)",
      "title": "Community Project Funding/Congressionally Directed Spending Construction - Mobile Lung Screening Program",
      "award_number": "1CE1HS52205?01?00",
      "sponsor": "Health Resources and Services Administration (HRSA)",
      "investigators": [
        {
          "name": "Gray, J.",
          "role": "PD/PI"
        }
      ]
    },
    {
      "description": "Title: Race-related differential RNA splicing: novel targets for precision oncology in non-small cell lung cancer  \nAward Number: 1R01CA253312-01  \nSponsor: National Cancer Institute (NCI)  \nGray, J. (PD/PI)",
      "title": "Race-related differential RNA splicing: novel targets for precision oncology in non-small cell lung cancer",
      "award_number": "1R01CA253312-01",
      "sponsor": "National Cancer Institute (NCI)",
      "source": "NCI",
      "investigators": [
        {
          "name": "Gray, J.",
          "role": "PD/PI"
        }
      ]
    },
    {
      "description": "Title: Southwest Oncology Group (SWOG) Appointment  \nAward Number: 5U10CA180888-11 Revised  \nSponsor: National Cancer Institute (NCI)  \nGray, J. (PD/PI)",
      "title": "Southwest Oncology Group (SWOG) Appointment",
      "award_number": "5U10CA180888-11 Revised",
      "sponsor": "National Cancer Institute (NCI)",
      "source": "NCI",
      "investigators": [
        {
          "name": "Gray, J.",
          "role": "PD/PI"
        }
      ]
    },
    {
      "description": "Title: Cancer Trials Support Unit (CTSU) Phase II Supplemental Payments - Master Lung Protocol  \nAward Number: HHSN26120622012C  \nSponsor: National Cancer Institute (NCI)  \nGray, J. (PD/PI)",
      "title": "Cancer Trials Support Unit (CTSU) Phase II Supplemental Payments - Master Lung Protocol",
      "award_number": "HHSN26120622012C",
      "sponsor": "National Cancer Institute (NCI)",
      "source": "NCI",
      "investigators": [
        {
          "name": "Gray, J.",
          "role": "PD/PI"
        }
      ]
    }
  ],
  "participating_trials": [
    {
      "trial_url": "https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-20386/",
      "trial_id": "20386",
      "title": "Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC",
      "condition": "Thoracic",
      "intervention": "Difluoromethylornithine (); Pembrolizumab (Keytruda)",
      "status": "OPEN (SUSPENDED)"
    },
    {
      "trial_url": "https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-20767/",
      "trial_id": "20767",
      "title": "Integration of Immunotherapy into Adjuvant Therapy For Resected NSCLC: Alchemist Chemo-IO",
      "condition": "Thoracic",
      "intervention": "Alimta (Pemetrexed); Gemzar (gemcitabine); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxol (paclitaxel); carboplatin (); cisplatin (); gemcitabine (); paclitaxel ()",
      "status": "Open"
    },
    {
      "trial_url": "https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-21184/",
      "trial_id": "21184",
      "title": "Thoracic Program Trial Selection Protocol",
      "condition": "Thoracic",
      "status": "Open"
    },
    {
      "trial_url": "https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-21626/",
      "trial_id": "21626",
      "title": "A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors",
      "condition": "Thoracic",
      "intervention": "Alimta (Pemetrexed); MK-1084 (); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); carboplatin ()",
      "status": "Open"
    },
    {
      "trial_url": "https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-21630/",
      "trial_id": "21630",
      "title": "Prospective Trial to Assess Real-world Outcomes and Predictive Biomarkers of Response to Pembrolizumab with or without Chemotherapy in Black Patients with NSCLC",
      "condition": "Thoracic",
      "intervention": "Abraxane (); Alimta (Pemetrexed); Nab-paclitaxel (Abraxane); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxol (paclitaxel); carboplatin (); cisplatin (); paclitaxel ()",
      "status": "Open"
    },
    {
      "trial_url": "https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-21951/",
      "trial_id": "21951",
      "title": "A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (STAR-121)",
      "condition": "Thoracic",
      "intervention": "Alimta (Pemetrexed); Domvanalimab (); Nab-paclitaxel (Abraxane); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxol (paclitaxel); Zimberelimab (); carboplatin (); cisplatin (); paclitaxel ()",
      "status": "Open"
    },
    {
      "trial_url": "https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-23180/",
      "trial_id": "23180",
      "title": "A Phase 1b/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody-Drug Conjugate (ADC), in Combination with Atezolizumab with or without Carboplatin as First-line Induction or Maintenance, in Subjects with Extensive-stage Small Cell Lung Cancer (ES-SCLC)",
      "condition": "Thoracic",
      "intervention": "Atezolizumab (Tecentriq); DS-7300a (I-DXd); I-DXd (); Paraplatin (carboplatin); carboplatin ()",
      "status": "Open"
    },
    {
      "trial_url": "https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-23182/",
      "trial_id": "23182",
      "title": "A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer",
      "condition": "Thoracic",
      "intervention": "Pembrolizumab (Keytruda); Placebo (); V940 ()",
      "status": "Open"
    },
    {
      "trial_url": "https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-23579/",
      "trial_id": "23579",
      "title": "A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02",
      "condition": "Thoracic",
      "intervention": "AMP-514 (Durvalumab); Durvalumab (); MEDI4736 (Durvalumab); Olomorasib/Placebo (); Pembrolizumab (Keytruda)",
      "status": "Open"
    }
  ],
  "lab_page_url": "https://www.justice-program.com/",
  "google_scholar_url": "",
  "photo_url": "https://www.moffitt.org/globalassets/images/researchers_bio/GrayJhanelle_3726.jpg",
  "contact": {
    "contact_url": "https://eforms.moffitt.org/ContactResearchersForm?PERID=3726"
  },
  "content_hash": "d05159a6c915b9d0dfd522ccddddca15e711dce1a7fb5e400c1dd1b1611f2b5c",
  "researcher_name": "jhanelle gray",
  "department": "tumor microenvironment and metastasis"
}